# Let's Talk Risk!

Where MedTech professionals gain clarity and confidence to navigate complex risk, quality, and leadership challenges.

Page: <https://rssamplifier.com/naveenagarwalphd-substack-com>  
Feed: <https://rssamplifier.com/naveenagarwalphd-substack-com.md>

---

## [QMSR QuickTake #38: "Documented" Does Not Mean Paper-Only](https://naveenagarwalphd.substack.com/p/qmsr-quicktake-38-documented-does-mean-paper-only)

_2026-08-18_

Under QMSR, a documented QMS processes must be more than written; it must be established, implemented, and maintained.

## [TAI #38: Are We Asking Too Much of FMEA?](https://naveenagarwalphd.substack.com/p/tai-38-are-we-asking-too-much-of-fmea)

_2026-08-17_

FMEA is valuable, but complex risks of harm may require pathway-based analysis to understand how events combine and controls interact.

## [LTR 163: FDA’s New Risk Lens Under QMSR](https://naveenagarwalphd.substack.com/p/ltr-163-fdas-new-risk-lens-under-qmsr)

_2026-08-14_

Allyson Mullen examines how QMSR is changing FDA’s approach to risk, inspections, quality agreements, and accountability across the quality system.

[Listen](https://api.substack.com/feed/podcast/210908159/6ded0fa2d9b3fb3a6c431ece56339119.mp3)

## [QMSR QuickTake #37: FDA Removed the Definitions, Not the Expectations](https://naveenagarwalphd.substack.com/p/qmsr-quicktake-37-fda-removed-the-definitions-not-the-expectations)

_2026-08-11_

QMSR removes explicit definitions for process and design validation, but not the underlying validation obligations.

## [TAI #37: Do We Really Understand Risk Control Effectiveness?](https://naveenagarwalphd.substack.com/p/tai-37-do-we-really-understand-risk-control-effectiveness)

_2026-08-10_

If we cannot explain how controls change the pathway to harm, we cannot confidently define, measure, or monitor their effectiveness.

## [Deep Dive: First FDA Warning Letter Under QMSR](https://naveenagarwalphd.substack.com/p/deep-dive-first-fda-warning-letter-under-qmsr)

_2026-08-07 · Naveen Agarwal, Ph.D._

What the Linemaster warning letter reveals about FDA’s emerging inspection and enforcement approach.

[Listen](https://api.substack.com/feed/podcast/209510184/4dd49aeee193876bf7dc9919d07fdc9f.mp3)

## [QMSR QuickTake #36: Why Batch and Lot Still Matter](https://naveenagarwalphd.substack.com/p/qmsr-quicktake-36-why-batch-and-lot-still-matter)

_2026-08-04_

FDA retained the batch/lot definition because QMSR needs clarity around the affected product population when manufacturers evaluate nonconformity, correction, CAPA, traceability, and risk.

## [TAI #36: When The Average Hides Uneven Benefit-Risk](https://naveenagarwalphd.substack.com/p/tai-36-when-the-average-hides-uneven-benefit-risk)

_2026-08-03_

A device may appear safe and effective overall while vulnerable patient subgroups experience a meaningfully less favorable benefit-risk balance.

## [LTR 162: Using HHE for Risk-Based Decisions](https://naveenagarwalphd.substack.com/p/ltr-162-using-hhe-for-risk-based-decisions)

_2026-07-31_

Kerry Flecknoe explains how ISO 14971 can turn Health Hazard Evaluations into consistent, defensible postmarket risk decisions.

[Listen](https://api.substack.com/feed/podcast/208987776/b899e3f5cc327b856ac973dfc0d15f95.mp3)

## [Browse ThreatCrush Modules (Sponsored)](https://crawlproof.com/a/xzannSwUJM6o)

_2026-07-31 · **Sponsored**_

Install community-built security modules to extend real-time threat intelligence and monitoring

## [QMSR QuickTake #35: CAPA Effectiveness Is Not a Closure Checkbox](https://naveenagarwalphd.substack.com/p/qmsr-quicktake-35-capa-effectiveness-not-a-clousure-checkbox)

_2026-07-28_

CAPA effectiveness is not proven by completion alone; it requires predefined criteria and evidence scaled to the underlying risk.